|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|
| Operating expenses: | |
| Acquired in-process research and development | |
| Research and development expense | |
| General and administrative expense | |
| Change in fair value of contingent consideration | |
| Total operating expenses | |
| Loss from operations | |
| Other income (expense): | |
| Interest expense | |
| Foreign exchange gain (loss) | |
| Interest income | |
| Loss before income taxes | |
| Income tax benefit | |
| Net loss | |
| Net loss per share of common stock, basic | |
| Net loss per share of common stock, diluted | |
| Weighted Average Number of Shares Outstanding, Basic | |
| Weighted Average Number of Shares Outstanding, Diluted | |
| Other comprehensive income: | |
| Foreign currency translation adjustment | |
| Other comprehensive (loss) income | |
| Total comprehensive loss |
Loading...
